Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-10-28
1999-07-06
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514256, 514269, 514272, 514274, 514275, 514303, 514346, 514349, 514350, 514351, 514352, 514354, 514355, 514356, 514357, 514369, 514370, 514371, 514393, 514394, 514395, 514396, 514398, 514399, 514400, 514401, 514418, 514419, 544297, 544311, 544312, 544314, 544315, 544316, 544317, 544318, 544321, 544323, 544326, 544327, 544329, 544332, 544335, 546118, 546122, 546123, 546290, 546291, 546292, 546293, 546294, 546296, 546297, 546298, 546299, 546300, 546301, 546304, 546305, 546306, 546307, 546308, 546309, 546310,
Patent
active
059197927
ABSTRACT:
This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
REFERENCES:
patent: 3465001 (1969-09-01), Bolhofer et al.
patent: 4195093 (1980-03-01), Laforest et al.
patent: 5260277 (1993-11-01), McKenzie
patent: 5308852 (1994-05-01), Girard et al.
patent: 5332754 (1994-07-01), Nakai et al.
patent: 5378715 (1995-01-01), Stein et al.
patent: 5416099 (1995-05-01), Hartman et al.
patent: 5455243 (1995-10-01), Duggan et al.
patent: 5506240 (1996-04-01), Schmidlin et al.
patent: 5523302 (1996-06-01), Cain et al.
patent: 5534524 (1996-07-01), Bonewald et al.
patent: 5668159 (1997-09-01), Jin et al.
patent: 5723499 (1998-03-01), Charpentier et al.
Xue et al., Biorg. & Medic. Chem. Lett. (1996), vol. 6, No. 3, pp. 339-344, "Design, synthesis and in vitro activities of a series of benzimidazole/benzoxazole glycoprotein . . . ".
Duggan Mark E.
Hartman George D.
Hoffman William F.
Ihle Nathan C.
Coleman Brenda
Durette Philippe L.
Merck & Co. , Inc.
Raymond Richard L.
Sabatelli Anthony D.
LandOfFree
Integrin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-899250